CHILDRENS HOSPITAL MEDICAL CENTER

Type: Teaching hospital
Where: Akron, OH
Medicare CCN: 363303
Received: $349,290 in 168 records, 2019 ($113,134 general, $236,156 research)
Source: CMS Open Payments search ↗

On this site

Nonprofit: CHILDRENS HOSPITAL MEDICAL CENTER Fuzzy (name and state)

By year

Program year	Kind	Records	Amount
2019	General payment	79	$113,134
2019	Research payment	89	$236,156

By company

Company	Records	Amount	Years
VERTEX PHARMACEUTICALS INCORPORATED	4	$54,457	2019
BIOVERATIV THERAPEUTICS INC.	6	$37,133	2019
UCB SA	5	$34,482	2019
KLS-Martin L.P.	4	$34,270	2019
Chiesi USA, Inc.	7	$30,890	2019
PFIZER INC.	28	$20,657	2019
Ipsen Biopharmaceuticals, Inc	7	$17,810	2019
AMAG Pharmaceuticals, Inc.	5	$15,379	2019
Shire North American Group Inc	8	$11,754	2019
Stryker Corporation	3	$11,180	2019
Amneal Pharmaceuticals LLC	5	$10,042	2019
Bracco Diagnostics Inc.	1	$9,754	2019
CSL Behring	6	$8,988	2019
UCB Biosciences Inc.	2	$8,390	2019
Hill-Rom Company, Inc	7	$6,410	2019
Allergan, Inc.	5	$6,266	2019
ABBVIE INC.	8	$5,076	2019
BioMarin Pharmaceutical Inc.	4	$4,600	2019
Zimmer Biomet Holdings, Inc.	3	$3,430	2019
SANOFI PASTEUR INC.	4	$3,000	2019
Merck Sharp & Dohme LLC	4	$2,150	2019
Novartis Pharmaceuticals Corporation	1	$2,000	2019
Gilead Sciences, Inc.	1	$2,000	2019
Bio-Rad Laboratories, Inc.	24	$1,782	2019
Mylan Pharmaceuticals Inc.	2	$1,500	2019
Oticon Medical, LLC	1	$845	2019
Alcresta Therapeutics, Inc.	1	$800	2019
GENZYME CORPORATION	1	$750	2019
Insulet Corporation	1	$750	2019
Luminex Corporation	1	$689	2019
VIVUS LLC	4	$674	2019
Medtronic USA, Inc.	1	$470	2019
Orthofix Medical, Inc.	1	$425	2019
Eli Lilly and Company	1	$189	2019
Siemens Medical Solutions USA, Inc.	1	$168	2019
GE HEALTHCARE	1	$122	2019

By nature of payment

Nature	Records	Amount
Research payment	89	$236,156
Space rental or facility fees (teaching hospital only)	30	$37,620
Grant	2	$30,000
Consulting Fee	6	$28,315
Education	5	$6,275
Travel and Lodging	5	$5,415
Gift	24	$1,782
Charitable Contribution	3	$1,290
Food and Beverage	2	$995
Compensation for services other than consulting, including serving as faculty or as a speaker at a v	1	$750
Honoraria	1	$689

Records

Date	Company	Amount	Nature	Form	Product	Study	Year
2019-12-31	Siemens Medical Solutions USA, Inc.	$168	Charitable Contribution	In-kind items and services			2019
2019-12-22	Bio-Rad Laboratories, Inc.	$75	Gift (3 payments)	Cash or cash equivalent	Bio-Plex Assays Device, BioPlex		2019
2019-12-20	BIOVERATIV THERAPEUTICS INC.	$6,476	Research payment	Cash or cash equivalent	FITUSIRAN Drug	ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without	2019
2019-12-17	Shire North American Group Inc	$1,000	Research payment	Cash or cash equivalent	HYQVIA Biological, IMMUNOLOGY	EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS	2019
2019-12-17	Insulet Corporation	$750	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	Omnipod Device, Insulin Pump		2019
2019-12-17	Shire North American Group Inc	$176	Research payment	Cash or cash equivalent	HYQVIA Biological, IMMUNOLOGY	EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS	2019
2019-12-11	AMAG Pharmaceuticals, Inc.	$7,867	Research payment	Cash or cash equivalent	FERAHEME Drug, PARENTERAL IRON REPLACEMENT	A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY COMPARED TO IRON SUCROSE, EFFICACY AND PHARM	2019
2019-12-06	ABBVIE INC.	$2,000	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	Creon Drug, Endocrinology		2019
2019-12-05	Oticon Medical, LLC	$845	Education (35 payments)	Cash or cash equivalent	PONTO BONE ANCHORED HEARING SYSTEM Device, Medical Device		2019
2019-12-05	Allergan, Inc.	$800	Research payment	Cash or cash equivalent	ZENPEP Drug, CYSTIC FIBROSIS	LONG-TERM STUDY IN US CYSTIC FIBROSIS PATIENTS RECEIVING DIGESTIVE ENZYME SUPPLEMENTS TO ASSESS ANY NARROWING OF THE LAR	2019
2019-12-05	ABBVIE INC.	$376	Research payment	Cash or cash equivalent	Creon Drug, Endocrinology	P12-792	2019
2019-12-05	VIVUS LLC	$126	Research payment	Cash or cash equivalent	PANCREAZE Drug, CYSTIC FIBROSIS	Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large I	2019
2019-12-01	PFIZER INC.	$45	Research payment	In-kind items and services	LYRICA Drug, NEUROSCIENCE;PAIN	A 12MONTH OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC SUBJE	2019
2019-11-28	AMAG Pharmaceuticals, Inc.	$1,080	Research payment	Cash or cash equivalent	FERAHEME Drug, PARENTERAL IRON REPLACEMENT	A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY COMPARED TO IRON SUCROSE, EFFICACY AND PHARM	2019
2019-11-27	PFIZER INC.	$318	Research payment	Cash or cash equivalent		A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG	2019
2019-11-27	Bio-Rad Laboratories, Inc.	$300	Gift (8 payments)	Cash or cash equivalent	Virotrol Device, Infections and Infectious Diseases		2019
2019-11-26	Amneal Pharmaceuticals LLC	$2,500	Research payment	Cash or cash equivalent	ZOMIG Drug, FAMILY MEDICINE	A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ZOLM	2019
2019-11-20	BIOVERATIV THERAPEUTICS INC.	$9,412	Research payment	Cash or cash equivalent	FITUSIRAN Drug	ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without	2019
2019-11-20	BIOVERATIV THERAPEUTICS INC.	$6,750	Research payment	Cash or cash equivalent	FITUSIRAN Drug	ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without	2019
2019-11-20	BIOVERATIV THERAPEUTICS INC.	$4,461	Research payment	Cash or cash equivalent	FITUSIRAN Drug	ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without	2019
2019-11-20	BIOVERATIV THERAPEUTICS INC.	$3,281	Research payment	Cash or cash equivalent	FITUSIRAN Drug	ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without	2019
2019-11-19	BIOVERATIV THERAPEUTICS INC.	$6,750	Research payment	Cash or cash equivalent	FITUSIRAN Drug	Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodi	2019
2019-11-14	BioMarin Pharmaceutical Inc.	$200	Research payment	Cash or cash equivalent	Kuvan Drug, PKU	PKU Demographics, Outcomes, and Safety Registry	2019
2019-11-12	Hill-Rom Company, Inc	$471	Travel and Lodging	In-kind items and services	Hill-Rom Heart and Respiration Rate Monitoring System powered by EarlySense Device, Breathing Frequency Monitor		2019
2019-11-12	Hill-Rom Company, Inc	$379	Travel and Lodging	In-kind items and services	Hill-Rom Heart and Respiration Rate Monitoring System powered by EarlySense Device, Breathing Frequency Monitor		2019
2019-11-12	Hill-Rom Company, Inc	$289	Food and Beverage	In-kind items and services	Hill-Rom Heart and Respiration Rate Monitoring System powered by EarlySense Device, Breathing Frequency Monitor		2019
2019-11-12	Hill-Rom Company, Inc	$56	Travel and Lodging	In-kind items and services	Hill-Rom Heart and Respiration Rate Monitoring System powered by EarlySense Device, Breathing Frequency Monitor		2019
2019-11-05	Ipsen Biopharmaceuticals, Inc	$2,838	Research payment	Cash or cash equivalent	DYSPORT Drug, Neurology	APhase IV, Prospective, Observational, Multicentre Study Evaluating the Effectiveness and Safety of Dysportabobotulinumt	2019
2019-11-01	PFIZER INC.	$45	Research payment	In-kind items and services	LYRICA Drug, NEUROSCIENCE;PAIN	A 12MONTH OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC SUBJE	2019
2019-10-30	ABBVIE INC.	$800	Research payment	Cash or cash equivalent	Humira Biological, Immunology	P10-262	2019
2019-10-29	Bio-Rad Laboratories, Inc.	$7	Gift	Cash or cash equivalent	Electrophoresis Reagents Device, Electrophoresis		2019
2019-10-24	Allergan, Inc.	$2,000	Education	Cash or cash equivalent			2019
2019-10-21	Bio-Rad Laboratories, Inc.	$25	Gift	Cash or cash equivalent	Liquichek Device, Controls		2019
2019-10-17	Ipsen Biopharmaceuticals, Inc	$250	Research payment	Cash or cash equivalent	DYSPORT Drug, Neurology	A Phase IV, Prospective, Observational, Multicentre Study Evaluating the Effectiveness and Safety of Dysport abobotulinu	2019
2019-10-16	VERTEX PHARMACEUTICALS INCORPORATED	$2,000	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	SYMDEKO Drug, CYSTIC FIBROSIS		2019
2019-10-07	CSL Behring	$8	Research payment	In-kind items and services	Privigen Biological, Immunology	Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP	2019
2019-10-03	Chiesi USA, Inc.	$1,000	Charitable Contribution	Cash or cash equivalent	CUROSURF Drug, NEONATOLOGY		2019
2019-10-03	Mylan Pharmaceuticals Inc.	$750	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	Xulane Drug, Women's Healthcare		2019
2019-10-01	PFIZER INC.	$45	Research payment	In-kind items and services	LYRICA Drug, NEUROSCIENCE;PAIN	A 12MONTH OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC SUBJE	2019
2019-09-30	Bio-Rad Laboratories, Inc.	$75	Gift (3 payments)	Cash or cash equivalent	Amplification Reagents Device, Amplification		2019
2019-09-24	Bio-Rad Laboratories, Inc.	$350	Gift (14 payments)	Cash or cash equivalent	Liquichek Device, Controls		2019
2019-09-21	Novartis Pharmaceuticals Corporation	$2,000	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent			2019
2019-09-19	Ipsen Biopharmaceuticals, Inc	$2,410	Research payment	Cash or cash equivalent	DYSPORT Drug, Neurology	A Phase IV, Prospective, Observational, Multicentre Study Evaluating the Effectiveness and Safety of Dysport abobotulinu	2019
2019-09-19	Chiesi USA, Inc.	$2,000	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	PERTZYE Drug, CYSTIC FIBROSIS		2019
2019-09-17	Hill-Rom Company, Inc	$4,132	Travel and Lodging	In-kind items and services	Hill-Rom Heart and Respiration Rate Monitoring System powered by EarlySense Device, Breathing Frequency Monitor		2019
2019-09-17	Hill-Rom Company, Inc	$705	Food and Beverage	In-kind items and services	Hill-Rom Heart and Respiration Rate Monitoring System powered by EarlySense Device, Breathing Frequency Monitor		2019
2019-09-17	Hill-Rom Company, Inc	$375	Travel and Lodging	In-kind items and services	Hill-Rom Heart and Respiration Rate Monitoring System powered by EarlySense Device, Breathing Frequency Monitor		2019
2019-09-12	Alcresta Therapeutics, Inc.	$800	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	RELIZORB Device, GASTROENTEROLOGY		2019
2019-09-11	BioMarin Pharmaceutical Inc.	$1,800	Research payment	Cash or cash equivalent	Kuvan Drug, PKU	PKU Demographics, Outcomes, and Safety Registry	2019
2019-09-10	Bracco Diagnostics Inc.	$9,754	Research payment	Cash or cash equivalent	ISOVUE Drug, CONTRAST MEDIA	A PROSPECTIVE, MULTICENTER OBSERVATIONAL STUDY TO EVALUATE THYROID FUNCTION OF PEDIATRIC SUBJECTS FROM BIRTH TO 3 YEARS	2019
2019-09-05	Chiesi USA, Inc.	$1,195	Consulting Fee	Cash or cash equivalent			2019
2019-09-04	Stryker Corporation	$4,095	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	SERRATO Device, THORACOLUMBAR		2019
2019-09-04	Stryker Corporation	$1,850	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	SERRATO Device, THORACOLUMBAR		2019
2019-09-01	PFIZER INC.	$45	Research payment	In-kind items and services	LYRICA Drug, NEUROSCIENCE;PAIN	A 12MONTH OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC SUBJE	2019
2019-08-28	AMAG Pharmaceuticals, Inc.	$1,080	Research payment	Cash or cash equivalent	FERAHEME Drug, PARENTERAL IRON REPLACEMENT	A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY COMPARED TO IRON SUCROSE, EFFICACY AND PHARM	2019
2019-08-26	Gilead Sciences, Inc.	$2,000	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent			2019
2019-08-23	Bio-Rad Laboratories, Inc.	$75	Gift (3 payments)	Cash or cash equivalent	Digital PCR Assays Device, PCR		2019
2019-08-15	Bio-Rad Laboratories, Inc.	$325	Gift (13 payments)	Cash or cash equivalent	Liquichek Device, Controls		2019
2019-08-15	Bio-Rad Laboratories, Inc.	$100	Gift (4 payments)	Cash or cash equivalent	Amplification Reagents Device, Amplification		2019
2019-08-15	Bio-Rad Laboratories, Inc.	$25	Gift	Cash or cash equivalent	Amplification Reagents Device, Amplification		2019
2019-08-14	PFIZER INC.	$750	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	PREVNAR - 13 Biological, VACCINES		2019
2019-08-08	CSL Behring	$350	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent			2019
2019-08-06	Amneal Pharmaceuticals LLC	$1,506	Research payment	Cash or cash equivalent	ZOMIG Drug, FAMILY MEDICINE	A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ZOLM	2019
2019-08-06	Amneal Pharmaceuticals LLC	$1,080	Research payment	Cash or cash equivalent	ZOMIG Drug, FAMILY MEDICINE	A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ZOLM	2019
2019-08-05	UCB Biosciences Inc.	$800	Research payment	Cash or cash equivalent	Vimpat Drug, Neurology	An open-label study to determine safety, tolerability, and efficacy of long-term Oral lacosamide (LCM) as adjunctive the	2019
2019-08-01	PFIZER INC.	$45	Research payment	In-kind items and services	LYRICA Drug, NEUROSCIENCE;PAIN	A 12MONTH OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC SUBJE	2019
2019-07-25	Bio-Rad Laboratories, Inc.	$25	Gift	Cash or cash equivalent	Lyphochek Device, Controls		2019
2019-07-25	Bio-Rad Laboratories, Inc.	$25	Gift	Cash or cash equivalent	Liquichek Device, Controls		2019
2019-07-25	Bio-Rad Laboratories, Inc.	$25	Gift	Cash or cash equivalent	Liquichek Device, Controls		2019
2019-07-24	AMAG Pharmaceuticals, Inc.	$4,272	Research payment	Cash or cash equivalent	FERAHEME Drug, PARENTERAL IRON REPLACEMENT	A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY COMPARED TO IRON SUCROSE, EFFICACY AND PHARM	2019
2019-07-23	Ipsen Biopharmaceuticals, Inc	$2,838	Research payment	Cash or cash equivalent	DYSPORT Drug, Neurology	A Phase IV, Prospective, Observational, Multicentre Study Evaluating the Effectiveness and Safety of Dysport abobotulinu	2019
2019-07-15	SANOFI PASTEUR INC.	$750	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	NO PRODUCT DISCUSSED Drug		2019
2019-07-10	Chiesi USA, Inc.	$12,500	Consulting Fee	Cash or cash equivalent			2019
2019-07-10	Chiesi USA, Inc.	$500	Consulting Fee	Cash or cash equivalent			2019
2019-07-08	SANOFI PASTEUR INC.	$750	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	NO PRODUCT DISCUSSED Drug		2019
2019-07-03	PFIZER INC.	$511	Research payment	Cash or cash equivalent		A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG	2019
2019-07-01	PFIZER INC.	$45	Research payment	In-kind items and services	LYRICA Drug, NEUROSCIENCE;PAIN	A 12MONTH OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC SUBJE	2019
2019-06-28	Bio-Rad Laboratories, Inc.	$25	Gift	Cash or cash equivalent	Liquichek Device, Controls		2019
2019-06-27	Allergan, Inc.	$519	Research payment	Cash or cash equivalent	ZENPEP Drug, CYSTIC FIBROSIS	LONG-TERM STUDY IN US CYSTIC FIBROSIS PATIENTS RECEIVING DIGESTIVE ENZYME SUPPLEMENTS TO ASSESS ANY NARROWING OF THE LAR	2019
2019-06-27	ABBVIE INC.	$244	Research payment	Cash or cash equivalent	Creon Drug, Endocrinology	P12-792	2019
2019-06-27	VIVUS LLC	$82	Research payment	Cash or cash equivalent	PANCREAZE Drug, CYSTIC FIBROSIS	Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large I	2019
2019-06-26	Chiesi USA, Inc.	$1,195	Consulting Fee	Cash or cash equivalent			2019
2019-06-20	Bio-Rad Laboratories, Inc.	$25	Gift	Cash or cash equivalent	Liquichek Device, Controls		2019
2019-06-17	Shire North American Group Inc	$6,750	Research payment	Cash or cash equivalent	HYQVIA Biological, IMMUNOLOGY	EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS	2019
2019-06-17	Shire North American Group Inc	$1,500	Research payment	Cash or cash equivalent	HYQVIA Biological, IMMUNOLOGY	EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS	2019
2019-06-17	Shire North American Group Inc	$878	Research payment	Cash or cash equivalent	HYQVIA Biological, IMMUNOLOGY	EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS	2019
2019-06-17	Shire North American Group Inc	$400	Research payment	Cash or cash equivalent	HYQVIA Biological, IMMUNOLOGY	EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS	2019
2019-06-14	Merck Sharp & Dohme LLC	$750	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	NEXPLANON Drug, WOMENS HEALTH		2019
2019-06-12	KLS-Martin L.P.	$2,310	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent			2019
2019-06-12	KLS-Martin L.P.	$1,960	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent			2019
2019-06-11	Bio-Rad Laboratories, Inc.	$25	Gift	Cash or cash equivalent	Digital PCR Assays Device, PCR		2019
2019-06-10	PFIZER INC.	$608	Research payment	Cash or cash equivalent		A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG	2019
2019-06-05	BioMarin Pharmaceutical Inc.	$400	Research payment	Cash or cash equivalent	Kuvan Drug, PKU	PKU Demographics, Outcomes, and Safety Registry	2019
2019-06-01	PFIZER INC.	$45	Research payment	In-kind items and services	LYRICA Drug, NEUROSCIENCE;PAIN	A 12MONTH OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC SUBJE	2019
2019-05-31	KLS-Martin L.P.	$15,000	Grant	Cash or cash equivalent			2019
2019-05-31	Bio-Rad Laboratories, Inc.	$100	Gift (4 payments)	Cash or cash equivalent	Amplification Reagents Device, Amplification		2019
2019-05-31	Bio-Rad Laboratories, Inc.	$25	Gift	Cash or cash equivalent	Chemistry Device, Chemistry		2019
2019-05-31	Bio-Rad Laboratories, Inc.	$25	Gift	Cash or cash equivalent	Liquichek Device, Controls		2019
2019-05-31	Bio-Rad Laboratories, Inc.	$25	Gift	Cash or cash equivalent	Biotestcell Device, Antiglobulin test		2019
2019-05-29	Chiesi USA, Inc.	$12,500	Consulting Fee	Cash or cash equivalent			2019
2019-05-28	Eli Lilly and Company	$189	Research payment	In-kind items and services		ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE	2019
2019-05-24	Merck Sharp & Dohme LLC	$350	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	ROTATEQ Biological, VACCINE		2019
2019-05-23	UCB SA	$13,905	Research payment	Cash or cash equivalent		AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PADSEVONILAS ADJUNCTIVE TREATMENT OF	2019
2019-05-23	CSL Behring	$6,750	Research payment	Cash or cash equivalent	Privigen Biological, Immunology	A randomized, openlabel, prospective, multicenter study designed to investigate 2 dose regimens in pediatric subjects 2	2019
2019-05-23	CSL Behring	$1,500	Research payment	Cash or cash equivalent	Privigen Biological, Immunology	A randomized, openlabel, prospective, multicenter study designed to investigate 2 dose regimens in pediatric subjects 2	2019
2019-05-14	Bio-Rad Laboratories, Inc.	$25	Gift	Cash or cash equivalent	Virotrol Device, Infections and Infectious Diseases		2019
2019-05-14	Bio-Rad Laboratories, Inc.	$25	Gift	Cash or cash equivalent	Liquichek Device, Controls		2019
2019-05-14	Bio-Rad Laboratories, Inc.	$25	Gift	Cash or cash equivalent	Virotrol Device, Infections and Infectious Diseases		2019
2019-05-14	Bio-Rad Laboratories, Inc.	$25	Gift	Cash or cash equivalent	Liquichek Device, Controls		2019
2019-05-09	ABBVIE INC.	$162	Research payment	Cash or cash equivalent	Humira Biological, Immunology	P10-262	2019
2019-05-08	Zimmer Biomet Holdings, Inc.	$750	Education	Cash or cash equivalent	Persona Device, Knees		2019
2019-05-07	UCB SA	$2,160	Research payment	Cash or cash equivalent	Briviact Drug, Neurology	OPEN-LABEL, SINGLE-ARM, MULTICENTER, LONG-TERM STUDY TO EVALUATE SAFETY AND EFFICACY OF BRIVARACETAM USED AS ADJUNCTIVE	2019
2019-05-01	PFIZER INC.	$888	Research payment	In-kind items and services	ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE	A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG	2019
2019-05-01	PFIZER INC.	$300	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	EUCRISA Drug, DERMATOLOGY		2019
2019-05-01	PFIZER INC.	$300	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	PREVNAR - 13 Biological, VACCINES		2019
2019-05-01	PFIZER INC.	$45	Research payment	In-kind items and services	LYRICA Drug, NEUROSCIENCE;PAIN	A 12MONTH OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC SUBJE	2019
2019-04-29	Luminex Corporation	$689	Honoraria	In-kind items and services	Medical Supply, Product		2019
2019-04-26	Medtronic USA, Inc.	$470	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent			2019
2019-04-23	Ipsen Biopharmaceuticals, Inc	$5,676	Research payment	Cash or cash equivalent	DYSPORT Drug, Neurology	A Phase IV, Prospective, Observational, Multicentre Study Evaluating the Effectiveness and Safety of Dysport abobotulinu	2019
2019-04-23	Amneal Pharmaceuticals LLC	$2,160	Research payment	Cash or cash equivalent	ZOMIG Drug, FAMILY MEDICINE	A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ZOLM	2019
2019-04-23	UCB SA	$2,160	Research payment	Cash or cash equivalent	Briviact Drug, Neurology	A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF INTRAVENOUS BRIVARACETAM I	2019
2019-04-19	Stryker Corporation	$5,235	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	TRIDENT Device, HIPS		2019
2019-04-15	PFIZER INC.	$1,027	Research payment	Cash or cash equivalent		A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG	2019
2019-04-11	SANOFI PASTEUR INC.	$750	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	NO PRODUCT DISCUSSED Drug		2019
2019-04-09	Allergan, Inc.	$800	Research payment	Cash or cash equivalent	ZENPEP Drug, CYSTIC FIBROSIS	LONG-TERM STUDY IN US CYSTIC FIBROSIS PATIENTS RECEIVING DIGESTIVE ENZYME SUPPLEMENTS TO ASSESS ANY NARROWING OF THE LAR	2019
2019-04-09	ABBVIE INC.	$376	Research payment	Cash or cash equivalent	Creon Drug, Endocrinology	P12-792	2019
2019-04-09	Shire North American Group Inc	$300	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent			2019
2019-04-09	VIVUS LLC	$126	Research payment	Cash or cash equivalent	PANCREAZE Drug, CYSTIC FIBROSIS	Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large I	2019
2019-04-05	GENZYME CORPORATION	$750	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	DUPIXENT Drug, IMMUNOLOGY		2019
2019-04-04	Mylan Pharmaceuticals Inc.	$750	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	Xulane Drug, Women's Healthcare		2019
2019-04-02	Shire North American Group Inc	$750	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent			2019
2019-04-01	PFIZER INC.	$45	Research payment	In-kind items and services	LYRICA Drug, NEUROSCIENCE;PAIN	A 12MONTH OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC SUBJE	2019
2019-03-22	Zimmer Biomet Holdings, Inc.	$1,930	Education	Cash or cash equivalent	Arcos Device, Hips		2019
2019-03-22	PFIZER INC.	$750	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	PREVNAR - 13 Biological, VACCINES		2019
2019-03-18	Merck Sharp & Dohme LLC	$750	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	ROTATEQ Biological, VACCINE		2019
2019-03-18	Merck Sharp & Dohme LLC	$300	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	ROTATEQ Biological, VACCINE		2019
2019-03-13	PFIZER INC.	$8,713	Research payment	Cash or cash equivalent		A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG	2019
2019-03-13	BioMarin Pharmaceutical Inc.	$2,200	Research payment	Cash or cash equivalent	Kuvan Drug, PKU	PKU Demographics, Outcomes, and Safety Registry	2019
2019-03-13	UCB SA	$192	Research payment	In-kind items and services		AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PADSEVONILAS ADJUNCTIVE TREATMENT OF	2019
2019-03-11	Zimmer Biomet Holdings, Inc.	$750	Education	Cash or cash equivalent	Comprehensive Anatomic Device, Extremities		2019
2019-03-01	SANOFI PASTEUR INC.	$750	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	NO PRODUCT DISCUSSED Drug		2019
2019-03-01	PFIZER INC.	$45	Research payment	In-kind items and services	LYRICA Drug, NEUROSCIENCE;PAIN	A 12MONTH OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC SUBJE	2019
2019-02-28	GE HEALTHCARE	$122	Charitable Contribution	Cash or cash equivalent			2019
2019-02-26	CSL Behring	$22	Research payment	In-kind items and services	Privigen Biological, Immunology	Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP	2019
2019-02-18	PFIZER INC.	$2,664	Research payment	In-kind items and services	ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE	A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG	2019
2019-02-18	PFIZER INC.	$207	Research payment	In-kind items and services	ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE	A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG	2019
2019-02-18	PFIZER INC.	$103	Research payment	In-kind items and services	ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE	A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG	2019
2019-02-14	Orthofix Medical, Inc.	$425	Consulting Fee	Cash or cash equivalent	Spinal-Stim Osteogenesis Stimulator Device, STIMULATOR, BONE GROWTH, NON-INVASIVE		2019
2019-02-14	Ipsen Biopharmaceuticals, Inc	$250	Research payment	Cash or cash equivalent	DYSPORT Drug, Neurology	A Phase IV, Prospective, Observational, Multicentre Study Evaluating the Effectiveness and Safety of Dysport abobotulinu	2019
2019-02-12	CSL Behring	$357	Research payment	In-kind items and services	Privigen Biological, Immunology	Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP	2019
2019-02-05	ABBVIE INC.	$108	Research payment	Cash or cash equivalent	Humira Biological, Immunology	P10-262	2019
2019-02-01	PFIZER INC.	$45	Research payment	In-kind items and services	LYRICA Drug, NEUROSCIENCE;PAIN	A 12MONTH OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC SUBJE	2019
2019-01-23	KLS-Martin L.P.	$15,000	Grant	Cash or cash equivalent			2019
2019-01-22	Ipsen Biopharmaceuticals, Inc	$3,547	Research payment	Cash or cash equivalent	DYSPORT Drug, Neurology	A Phase IV, Prospective, Observational, Multicentre Study Evaluating the Effectiveness and Safety of Dysport abobotulinu	2019
2019-01-17	Allergan, Inc.	$2,146	Research payment	Cash or cash equivalent	ZENPEP Drug, CYSTIC FIBROSIS	LONG-TERM STUDY IN US CYSTIC FIBROSIS PATIENTS RECEIVING DIGESTIVE ENZYME SUPPLEMENTS TO ASSESS ANY NARROWING OF THE LAR	2019
2019-01-17	ABBVIE INC.	$1,008	Research payment	Cash or cash equivalent	Creon Drug, Endocrinology	P12-792	2019
2019-01-17	VIVUS LLC	$339	Research payment	Cash or cash equivalent	PANCREAZE Drug, CYSTIC FIBROSIS	Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large I	2019
2019-01-15	UCB Biosciences Inc.	$7,590	Research payment	Cash or cash equivalent	Vimpat Drug, Neurology	A MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF INTRAVENOUS LACOSAMIDE AS REPLACEMENT FOR	2019
2019-01-15	Amneal Pharmaceuticals LLC	$2,795	Research payment	Cash or cash equivalent	ZOMIG Drug, FAMILY MEDICINE	A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ZOLM	2019
2019-01-10	UCB SA	$16,065	Research payment	Cash or cash equivalent		A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FINDING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PADSEVONIL AS	2019
2019-01-08	VERTEX PHARMACEUTICALS INCORPORATED	$1,800	Research payment	Cash or cash equivalent		A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Subjects	2019
2019-01-03	AMAG Pharmaceuticals, Inc.	$1,080	Research payment	Cash or cash equivalent	FERAHEME Drug, PARENTERAL IRON REPLACEMENT	A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY COMPARED TO IRON SUCROSE, EFFICACY AND PHARM	2019
2019-01-01	VERTEX PHARMACEUTICALS INCORPORATED	$28,448	Research payment	Cash or cash equivalent		A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy	2019
2019-01-01	VERTEX PHARMACEUTICALS INCORPORATED	$22,208	Research payment	Cash or cash equivalent		A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and	2019
2019-01-01	PFIZER INC.	$2,664	Research payment	In-kind items and services	ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE	A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG	2019
2019-01-01	PFIZER INC.	$207	Research payment	In-kind items and services	ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE	A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG	2019
2019-01-01	PFIZER INC.	$103	Research payment	In-kind items and services	ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE	A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG	2019
2019-01-01	PFIZER INC.	$45	Research payment	In-kind items and services	LYRICA Drug, NEUROSCIENCE;PAIN	A 12MONTH OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC SUBJE	2019

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.